Clinical Trials Browser

Completed × INDUSTRY × mirdametinib × Clear all

NCT03905148 2026-01-07

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult